| scholarly article | Q13442814 |
| P2093 | author name string | Jinming Yu | |
| Linlin Wang | |||
| Cheng Li | |||
| Xindong Sun | |||
| Shijiang Wang | |||
| Yiyue Xu | |||
| Meiying Guo | |||
| Butuo Li | |||
| P2860 | cites work | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. | Q38978231 |
| VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer | Q39252038 | ||
| Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. | Q39582827 | ||
| Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. | Q40535967 | ||
| Strategies targeting angiogenesis in advanced non-small cell lung cancer | Q41593429 | ||
| Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | Q42073978 | ||
| Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. | Q43041612 | ||
| BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer | Q51628000 | ||
| Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab | Q52758014 | ||
| Neutrophils in primary gastric tumors are correlated with neutrophil infiltration in tumor-draining lymph nodes and the systemic inflammatory response. | Q55408537 | ||
| Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8 | Q61609536 | ||
| Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy | Q79609692 | ||
| Immunomodulatory effects of VEGF: Clinical implications of VEGF-targeted therapy in human cancer | Q83910558 | ||
| The parallel lives of angiogenesis and immunosuppression: cancer and other tales | Q84975992 | ||
| Promising early results for immunotherapy-antiangiogenesis combination | Q86048163 | ||
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 | ||
| C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review | Q26771557 | ||
| Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis | Q27001079 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab | Q28388270 | ||
| Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. | Q34458617 | ||
| Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis | Q34928194 | ||
| The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. | Q35274955 | ||
| Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis | Q35884531 | ||
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients | Q37269186 | ||
| Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer | Q37362884 | ||
| Mechanisms of resistance to antiangiogenesis therapy | Q37710828 | ||
| Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis | Q37716520 | ||
| Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis | Q37744341 | ||
| The platelet contribution to cancer progression | Q37805788 | ||
| Tumor angiogenesis: molecular pathways and therapeutic targets | Q37953773 | ||
| Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. | Q38081572 | ||
| Monocyte subpopulations in angiogenesis. | Q38189962 | ||
| Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis | Q38611054 | ||
| Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? | Q38835701 | ||
| P433 | issue | 21 | |
| P921 | main subject | bevacizumab | Q413299 |
| P304 | page(s) | 5082-5089 | |
| P577 | publication date | 2019-08-28 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients | |
| P478 | volume | 10 |
| Q102210873 | Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer | cites work | P2860 |
Search more.